Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
Guibal et al (1) have demonstrated that contrast-enhanced US-derived parameters provide a noninvasive measure of tumor angiogenesis and, in particular, of the revascularization occurring after discontinuation of an antivascular endothelial growth factor (anti-VEGF) therapy. If these results can be reproduced in future clinical trials, contrast-enhanced US will enable the accurate monitoring of patient response to antiangiogenic therapies (including treatment suspensions), which should improve clinical outcomes.
Forsberg
Flemming
F
Department of Radiology, Thomas Jefferson University Hospital, Suite 763J, Main Building, 132 S 10th St, Philadelphia, PA 19107, USA. flemming.forsberg@jefferson.edu
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D003287:Contrast Media; D006801:Humans; D021621:Imaging, Three-Dimensional; D051379:Mice; D045423:Microbubbles; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003287:Contrast Media; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab